De-Risked TCRm Antibodies
Unlocking Intracellular Cancer Targets for Novel Treatment Options.
Where do you want to start?
Pipeline Overview
Five programs. One platform.
Five TCRm-based T-cell engager programs targeting tumor-restricted intracellular cancer antigens, led by MAGE-A4 in preclinical development, with MAGE-A3/A9, PRAME, MAGE-A1, and KK-LC-1 advancing through lead optimization and discovery.
This foundation powers BioCopy’s next-generation anti-pHLA T-cell engagers and provides a versatile platform for extending validated targets into cell-based therapies, antibody-drug conjugates, and mRNA-encoded in vivo approaches—opening multiple paths to best- and first-in-class therapeutic opportunities
Bispecific Antibody Pipeline for Solid Cancers
Leveraging our proprietary ValidaTe® platform, we are advancing a unique portfolio of TCR‑mimic (TCRm) T‑cell engagers (TCEs) that unlock intracellular targets inaccessible to conventional antibodies, aiming for first- or best-in-class cancer therapeutics.
Five programs spanning target credentialing through preclinical development, built on the ValidaTeR discovery platform:
Therapeutic Areas
Unlocking new treatment opportunities across the most challenging diseases
Our primary focus is cancer, targeting major indications with high unmet medical need, particularly patients with advanced or late-line disease who have limited or no remaining treatment options. By targeting cancer-testis antigens and other tumor-associated intracellular targets expressed across multiple tumor types, BioCopy aims to address significant patient needs while accessing large and underserved markets.
Our initial indications have been selected based on a combination of medical need, target biology, prevalence, and therapeutic potential. Beyond oncology, our proprietary target-recognition approach offers the potential to extend into infectious and autoimmune diseases, broadening the long-term reach of the platform.
Get in touch
Let’s redefine drug discovery —
together.
Whether you want to partner, invest, join, or simply learn more — tell us what you’re working on. We’ll route you to the right person.
- Validated anti-pHLA therapeutics — not just predictions
- Confidential by default · NDA on request
- No sales calls — only direct conversations with our team
Send us a message
By submitting, you agree to our privacy policy. We'll never share your data.